temozolomide has been researched along with Injuries, Radiation in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma." | 9.15 | [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. ( Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 7.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "The case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described." | 7.76 | Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. ( Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S, 2010) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 7.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)." | 7.75 | Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. ( Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma." | 5.15 | [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. ( Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011) |
| "Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients." | 3.79 | Defining pseudoprogression in glioblastoma multiforme. ( Bechter, OE; Clement, PM; De Vleeschouwer, S; Demaerel, P; Geussens, Y; Menten, J; Sciot, R; Van Calenbergh, F; Van Gool, S; Van Mieghem, E; Wilms, G; Wozniak, A, 2013) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 3.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "The case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described." | 3.76 | Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. ( Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S, 2010) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 3.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)." | 3.75 | Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. ( Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009) |
| "Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
| "Patients with multiple brain metastases from NSCLC aged ≥ 18 years, classified according to recursive partitioning analysis class I or II and with adequate organ functions were eligible." | 2.78 | Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. ( Altorjai, G; Dieckmann, K; Geissler, K; Hassler, MR; Knocke-Abulesz, TH; Marosi, C; Pfeifer, W, 2013) |
| "Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
| " Commenced 15 years ago, PRRT is now becoming established as first- and second-line therapy for gastroentero pancreatic neuroendocrine tumors (GEPNETs), and early treatment minimizes myelotoxicity, which is the most significant potential adverse event following PRRT." | 2.53 | Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. ( Kesavan, M; Turner, JH, 2016) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Gallitto, M | 1 |
| Savacool, M | 1 |
| Lee, A | 1 |
| Wang, TJC | 1 |
| Sisti, MB | 1 |
| Wee, CW | 1 |
| Kim, KS | 1 |
| Kim, CY | 1 |
| Han, JH | 1 |
| Kim, YJ | 1 |
| Kim, IA | 1 |
| Guo, L | 1 |
| Li, X | 1 |
| Chen, Y | 1 |
| Liu, R | 1 |
| Ren, C | 1 |
| Du, S | 1 |
| Park, YW | 1 |
| Choi, D | 1 |
| Park, JE | 1 |
| Ahn, SS | 1 |
| Kim, H | 1 |
| Chang, JH | 1 |
| Kim, SH | 1 |
| Kim, HS | 1 |
| Lee, SK | 1 |
| Gao, F | 1 |
| Zhao, W | 1 |
| Li, M | 1 |
| Ren, X | 1 |
| Jiang, H | 1 |
| Cui, Y | 1 |
| Lin, S | 1 |
| Winter, SF | 1 |
| Loebel, F | 1 |
| Loeffler, J | 1 |
| Batchelor, TT | 1 |
| Martinez-Lage, M | 1 |
| Vajkoczy, P | 1 |
| Dietrich, J | 1 |
| Kruser, TJ | 1 |
| Mehta, MP | 1 |
| Robins, HI | 1 |
| Van Mieghem, E | 1 |
| Wozniak, A | 1 |
| Geussens, Y | 1 |
| Menten, J | 1 |
| De Vleeschouwer, S | 1 |
| Van Calenbergh, F | 1 |
| Sciot, R | 1 |
| Van Gool, S | 1 |
| Bechter, OE | 1 |
| Demaerel, P | 1 |
| Wilms, G | 1 |
| Clement, PM | 1 |
| Hassler, MR | 1 |
| Pfeifer, W | 1 |
| Knocke-Abulesz, TH | 1 |
| Geissler, K | 1 |
| Altorjai, G | 1 |
| Dieckmann, K | 1 |
| Marosi, C | 1 |
| Iuchi, T | 1 |
| Hatano, K | 1 |
| Kodama, T | 1 |
| Sakaida, T | 1 |
| Yokoi, S | 1 |
| Kawasaki, K | 1 |
| Hasegawa, Y | 1 |
| Hara, R | 1 |
| Kesavan, M | 1 |
| Turner, JH | 1 |
| Peca, C | 1 |
| Pacelli, R | 1 |
| Elefante, A | 1 |
| Del Basso De Caro, ML | 1 |
| Vergara, P | 1 |
| Mariniello, G | 1 |
| Giamundo, A | 1 |
| Maiuri, F | 1 |
| Jakob, J | 1 |
| Wenz, F | 1 |
| Dinter, DJ | 1 |
| Ströbel, P | 1 |
| Hohenberger, P | 1 |
| Shibamoto, Y | 1 |
| Sugie, C | 1 |
| Iwata, H | 1 |
| Yang, I | 1 |
| Aghi, MK | 1 |
| Yaman, E | 1 |
| Buyukberber, S | 1 |
| Benekli, M | 1 |
| Oner, Y | 1 |
| Coskun, U | 1 |
| Akmansu, M | 1 |
| Ozturk, B | 1 |
| Kaya, AO | 1 |
| Uncu, D | 1 |
| Yildiz, R | 1 |
| Schreiber, S | 1 |
| Prox-Vagedes, V | 1 |
| Elolf, E | 1 |
| Brueggemann, I | 1 |
| Gademann, G | 1 |
| Galazky, I | 1 |
| Bartels, C | 1 |
| Payer, F | 1 |
| Matuschek, C | 1 |
| Bölke, E | 1 |
| Nawatny, J | 1 |
| Hoffmann, TK | 1 |
| Peiper, M | 1 |
| Orth, K | 1 |
| Gerber, PA | 1 |
| Rusnak, E | 1 |
| Lammering, G | 1 |
| Budach, W | 1 |
| Fang, HH | 1 |
| Nie, Q | 1 |
| Kang, JB | 1 |
| Li, FM | 1 |
| Cai, CL | 1 |
| Brown, P | 1 |
| Buckner, J | 1 |
| Piroth, MD | 1 |
| Gagel, B | 1 |
| Pinkawa, M | 1 |
| Stanzel, S | 1 |
| Asadpour, B | 1 |
| Eble, MJ | 1 |
| Brandes, AA | 1 |
| Franceschi, E | 1 |
| Tosoni, A | 1 |
| Blatt, V | 1 |
| Pession, A | 1 |
| Tallini, G | 1 |
| Bertorelle, R | 1 |
| Bartolini, S | 1 |
| Calbucci, F | 1 |
| Andreoli, A | 1 |
| Frezza, G | 1 |
| Leonardi, M | 1 |
| Spagnolli, F | 1 |
| Ermani, M | 1 |
| Brandsma, D | 1 |
| Stalpers, L | 1 |
| Taal, W | 1 |
| Sminia, P | 1 |
| van den Bent, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for temozolomide and Injuries, Radiation
| Article | Year |
|---|---|
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; N | 2016 |
Radiotherapy for metastatic brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cra | 2009 |
New advances that enable identification of glioblastoma recurrence.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioblastoma; | 2009 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
3 trials available for temozolomide and Injuries, Radiation
| Article | Year |
|---|---|
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemorad | 2011 |
12 other studies available for temozolomide and Injuries, Radiation
| Article | Year |
|---|---|
Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
Topics: Adult; Brain Neoplasms; Feasibility Studies; Female; Glioblastoma; Humans; Male; Prospective Studies | 2022 |
Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hippocampu | 2020 |
Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
Topics: Adult; Aged; Brain; Chemoradiotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Female; Gliob | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradi | 2013 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarb | 2009 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Female; Glioblastoma; Humans; Hypericu | 2010 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; | 2007 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |